KRAS mutations as prognostic and predictive markers in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 530-542

  Martin, Petra ^a   Leighl, Natasha B ^a   Tsao, Ming Sound ^a   Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cetuximab; Epidermal growth factor receptor; Erlotinib; Gefitinib; KRAS; Mutations; Non small cell lung cancer

Indexed keywords

ALKYLATING AGENT; ANTIMITOTIC AGENT; ARQ 197 209; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GANETESPIB; GEFITINIB; K RAS PROTEIN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RIDAFOROLIMUS; SALIRASIB; SELUMETINIB; SORAFENIB; TIVANTINIB; TRAMETINIB; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CELL DEATH; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DOSE RESPONSE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS (TOPIC); METASTASIS; MONOTHERAPY; ONCOGENE RAS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

EID: 84876416500     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318283d958     Document Type: Review

References (112)

1. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. JNCCN 2010;8:740-801.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64, 1.
3. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fuo-rine-18 fuorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-1464.
4. Siegel R, Naishadham D, Jemal A, et al. Cancer statistics. CA Cancer J Clin 2012;62:10-29.
5. Lau CL, D'Amico DA, Harpole DH Jr. Clinical and molecular prognostic factors and models for non-small cell lung cancer. In HI Pass, JB Mitchell, DH Johnson, et al (Eds.), Lung Cancer Principles and Practice, 2nd Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2000. Pp. 602-611.
6. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997;17:S37-S58.
7. Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988;2083-2088.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
9. Jänne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with geftinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004; 44:221-230.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 2004;350:2129-2139.
11. Marks JL, McLellan MD, Zakowski M F, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifes a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007;2:e426.
12. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identifcation of driver mutations in tumor specimens from 1, 000 patients with lung adenocar-cinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29:(Suppl; abstract CRA7506).
13. Graziano SL, Gamble G P, Newman NB, et al. Prognostic signifcance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17:668-675.
14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-acti-vated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310.
15. Riely GJ, Kris MG, Rosenbaum D, et al. Never smokers with lung adenocarcinoma frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
16. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
17. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
18. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457-2467.
19. Lee YJ, Kim JH, Kim SK, et al. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 2011;72:9-15.
20. Mitsudomi T, Onozato R, Kosaka T, et al. Smoking-related and nonsmoking-related carcinogensis in adenocarcinoma of the lung. J Clin Oncol 2008;26:(May 20 Suppl; abstract 22001).
21. Mack PC, Redman MW, Chansky K, et al. KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424. J Clin Oncol 2010;28:15s (Suppl; abstract 7013).
22. Harvey JJ. An unidentifed virus which causes the rapid production of tumours in mice. Nature 1964;204:1104-1105.
23. Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblas-tosis virus. J Natl Cancer Inst 1967;39:311-335.
24. Scolnick EM, Rands E, Williams D, Parks W P. Studies on the nucleic acid sequences of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma virus. J Virol 1973;12:458-463.
25. Vigil D, Cherfls J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10:842-857.
26. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-531.
27. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074.
28. Malumbres M, Barbacid M. RAS oncogenes: the frst 30 years. Nat Rev Cancer 2003;3:459-465.
29. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004;14:105-114.
30. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigen-esis. Adv Cancer Res 2009;102:19-65.
31. Dhillon AS, Hagan S, Rath O. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290.
32. Capelletti M, Wang X F, Gu L, et al. Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. J Clin Oncol 2010;28:15s (Suppl; abstract 7008).
33. Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic signifcance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003;39:1242-1250.
34. Scoccianti C, Vesin A, Martel G, et al. Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: EUELC cohort. Eur Respir J 2012 [Epub ahead of print].
35. Kern JA, Slebos RJ, Top B, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93:516-520.
36. Ma X, Vataire AL, Sun H, et al. TP53 AND KRAS Mutations as markers of outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer (NSCLC): The International Adjuvant Lung Cancer Trial (IALT) biological program. Annal Oncol 2008;19(Suppl 8):viii61.
37. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic signifcance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001;19:448-457.
38. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-5247.
39. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-139.
40. Tsao MS, Hainaut P, Bourredjem A, et al. LACE-bio pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol 2010;21:S1560.
41. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-565.
42. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.
43. Douillard J Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
44. Shepherd FA, Bourredjem A, Brambilla E, et al. Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. J Clin Oncol 2012;30:(Suppl; abstract 7007).
45. Rosell R, Molina F, Moreno I, et al. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 1995;12(Suppl 1):S59-S70.
46. Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997;15:285-291.
47. Broermann P, Junker K, Brandt BH, et al. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 2002;94:2055-2062.
48. Brady AK, McNeill JD, Judy B, et al. Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with frst-line chemotherapy. J Clin Oncol 2012;30 (Suppl; abstract 7595).
49. Levy B, Seetharamu N, Richardson S, et al. KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/peme-trexed based chemotherapy. J Clin Oncol 2012;30 (Suppl; abstract e18139).
50. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
51. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
52. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12(20 Pt 1):6049-6055.
53. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with geftinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042.
54. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896.
55. Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867-3874.
56. Schneider C P, Heigener D, Schott-von-Römer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlo-tinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol 2008;3:1446-1453.
57. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with geftinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 2009;4:318-325.
58. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-1612.
59. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with geftinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
60. Edward SK, Vera H, Tony M, Mark AS, et al. Geftinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
61. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766.
62. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-4120.
63. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3315.
64. Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012;30 (Suppl; abstract LBA7501).
65. Metro G, Chiaria R, Durantia S, et al. Impact of specifc mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 2012 [Epub ahead of print].
66. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab beneft in BMS099, a phase III study of cetuximab and frst-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-927.
67. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805.
68. Domine M, Izarzugaza Y, Rojo F, et al. KRAS mutations as predictive biomarker in patients with EGFR wild-type stage IV nonsquamous non-small cell lung cancer (NSCLC) recruited in a phase II clinical study with carboplatin-docetaxel-bevacizumab. J Clin Oncol 2012;30 (Suppl; abstract e18069).
69. Kabbinavar F, Miller VA, Johnson BE, O'Connor P, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for frst-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:15s (abstract 7526).
70. Johnson B, Miller V, Amler LC, et al. Biomarker evaluation in the randomized, double-blind, placebo-controlled, phase IIIb ATLAS trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Eur J Cancer 2009;7(3):5.
71. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-972.
72. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analy-sis of 22 studies. Lung Cancer 2010;69:272-278.
73. Appels NMGM, Jos H, Beijnen JH, Schellens JHM. Development of farnesyl transferase inhibitors: a review. Oncologist 2005;10:565-578.
74. Johnson BE, Heymach J V. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res 2004;10:4254s.
75. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl trans-ferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:1760-1766.
76. Eder JP Jr, Ryan D P, Appleman L, et al. Phase I clinical trial of the farne-syltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 2006;58:107-116.
77. Riely GJ, Johnson ML, Medina C, et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 2011;6:1435-1437.
78. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharma-cokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-2219.
79. Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010;70:2264-2273.
80. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-239.
81. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-4939.
82. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifes genetic modifers of therapeutic response. Nature 2012;483:613-617.
83. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the effcacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010;5:1630-1636.
84. AstraZeneca. A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Effcacy of AZD6244 (Hyd-Sulfate) in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV). In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Nov 05]. Available from: http://clinicaltrials. gov/show/NCT00890825 NLM Identifer: NCT00890825.
85. Janne PA, Shaw AT, Pereira JR et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30 (Suppl; abstract 7503)
86. M.D. Anderson Cancer Center BATTLE 2 Program. A Biomarker-Integrated Targeted Therapy Study In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).2000-[cited2012Apr05].Available from:http://clinicaltrials.gov/show/NCT01229150NLM Identifer: NCT01248247.
87. National Cancer Institute; National Institute of Health Clinical Center. Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer. In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Apr 05]. Available from: http://clini-caltrials.gov/show/NCT01229150 NLM Identifer: NCT01229150.
88. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacoki-netic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
89. Blumenschien. Proc Santa Monica Meeting, 2011.
90. GlaxoSmithKline. A Phase II, Open-label, Multicenter, Randomized Study to Assess the Effcacy and Safety of GSK1120212 Compared With Docetaxel in 2nd Line Subjects With Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IIIBwet-IV). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Nov 05]. Available from: http://clinicaltrials.gov/show/ NCT01362296 NLM Identifer: NCT01362296.
91. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:S7-S19.
92. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and bio-marker in cancer. Ther Adv Med Oncol 2011;3:S21-S35.
93. Daiichi Sankyo Inc.; Daiichi Sankyo Development Limited ArQule. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Nov 05]. Available from: http://clinicaltrials.gov/show/ NCT01244191 NLM Identifer: 01244191.
94. Daiichi Sankyo Co., Ltd. ARQULE and Daiichi Sankyo announce discontinuation of phase 3 marquee clinical trial in non-small cell lung cancer. [Press Release]. Press release. Available at: http://www.daiich-isankyo.com. Accessed February 2013.
95. ArQule. A Phase 2 Randomized Open-label Study of Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2011 Nov 05]. Available from: http://clinicaltrials.gov/show/ NCT01395758 NLM Identifer: 01395758.
96. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008;13:139-147.
97. Riely GJ, Brahmer JR, Planchard D, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. J Clin Oncol 2012;30 (Suppl; abstract 7531).
98. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
99. Sos ML, Michel K, Zander T, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009;119:1727-1740.
100. Acquaviva J, Smith D, Sang J, et al. Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012;11:2633-2643.
101. Wong K, Koczywas M, Goldman J W, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29 (Suppl; abstract 7500).
102. Synta Pharmaceuticals Corp. A randomized, Phase IIB/III study of Ganetespib (STA-9090) in combination with Docetaxel versus Docetaxel alone in subjects with Stage IIIb or IV Non-small-cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).2000-[cited 2012 Apr 05]. Available from: http://clinicaltrials.gov/show/ NCT013481265 NLM Identifer: 01348126.
103. Smit E, Dingemans AM, Thunnissen F, et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-Ras mutations. J Thorac Oncol 2010;5:719-720.
104. Mellema W W, Dingemans AMC, Groen HJM, et al. A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with KRAS mutation. AACR-IASLC 2011 (Abstract PR-5).
105. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
106. Kelly RJ, Rajan A, Force J, et al. Evaluation of KRAS mutations, angio-genic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17:1190-1199.
107. Humberto Lara-Guerra H, Waddell TK, Salvarrey MA, et al. Phase II study of preoperative geftinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 2009;27:6229-6236.
108. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-239.
109. Ratner ES, Keane FK, Tassi RA, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011. doi: 10.1038/onc.2011.539. [Epub ahead of print].
110. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-8540.
111. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28:4769-4777.
112. Mack PC, Gandara DR, Omori A, et al. KRAS mutation analysis in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for EGFR-directed therapies. J Thorac Oncol 2009; 4:S350 (abstr).